AnaptysBio Company Profile (NASDAQ:ANAB)

About AnaptysBio (NASDAQ:ANAB)

AnaptysBio logoAnaptysBio, Inc. is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ANAB
  • CUSIP: N/A
  • Web:
  • Market Cap: $565.51 million
  • Outstanding Shares: 20,269,000
Average Prices:
  • 50 Day Moving Avg: $24.81
  • 200 Day Moving Avg: $24.62
  • 52 Week Range: $15.17 - $30.71
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.85
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $11.82 million
  • Price / Sales: 44.19
  • Book Value: $5.44 per share
  • Price / Book: 4.74
  • EBIDTA: ($11,660,000.00)
  • Debt-to-Equity Ratio: 0.12%
  • Current Ratio: 13.56%
  • Quick Ratio: 13.57%
  • Average Volume: 51,378 shs.
  • Short Ratio: 2.76
Frequently Asked Questions for AnaptysBio (NASDAQ:ANAB)

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.57. View AnaptysBio's Earnings History.

Where is AnaptysBio's stock going? Where will AnaptysBio's stock price be in 2017?

5 analysts have issued 12-month price targets for AnaptysBio's shares. Their predictions range from $28.00 to $45.00. On average, they expect AnaptysBio's share price to reach $35.60 in the next year. View Analyst Ratings for AnaptysBio.

Who are some of AnaptysBio's key competitors?

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the folowing people:

  • Hamza Suria, President, Chief Executive Officer, Director
  • Dominic G. Piscitelli, Chief Financial Officer
  • Matthew Moyle Ph.D., Chief Scientific Officer
  • Marco Londei M.D., Chief Medical Officer
  • Hollings C. Renton III, Lead Independent Director
  • Carol G. Gallagher, Independent Director
  • Nicholas Lydon Ph.D., Independent Director
  • John P. Schmid, Independent Director
  • James A. Schoeneck, Independent Director

When did AnaptysBio IPO?

(ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

When did the company's lock-up period expire?

AnaptysBio's lock-up period expired on Tuesday, July 25th. AnaptysBio had issued 5,000,000 shares in its initial public offering on January 26th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who owns AnaptysBio stock?

AnaptysBio's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Hamilton Lane Advisors LLC (1.99%). Company insiders that own AnaptysBio stock include Healthcare Vii LP Frazier and Nicholas Lydon. View Institutional Ownership Trends for AnaptysBio.

How do I buy AnaptysBio stock?

Shares of AnaptysBio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AnaptysBio's stock price today?

One share of AnaptysBio stock can currently be purchased for approximately $25.77.

MarketBeat Community Rating for AnaptysBio (NASDAQ ANAB)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  15 (Vote Underperform)
Total Votes:  60
MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AnaptysBio (NASDAQ:ANAB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.60 (38.15% upside)

Analysts' Ratings History for AnaptysBio (NASDAQ:ANAB)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/10/2017Robert W. BairdInitiated CoverageOutperform -> Outperform$36.00HighView Rating Details
5/2/2017Stifel NicolausBoost Price TargetBuy$30.00 -> $35.00LowView Rating Details
4/18/2017Credit Suisse GroupReiterated RatingOutperform$34.00MediumView Rating Details
3/31/2017JMP SecuritiesReiterated RatingOutperform$45.00HighView Rating Details
3/29/2017WedbushLower Price TargetOutperform$33.00 -> $28.00HighView Rating Details
(Data available from 7/27/2015 forward)


Earnings History for AnaptysBio (NASDAQ:ANAB)
Earnings by Quarter for AnaptysBio (NASDAQ:ANAB)
Earnings History by Quarter for AnaptysBio (NASDAQ ANAB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.18)($0.75)$1.63 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for AnaptysBio (NASDAQ:ANAB)
2017 EPS Consensus Estimate: ($1.94)
2018 EPS Consensus Estimate: ($2.95)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.24)($0.24)($0.24)
Q2 20171($0.47)($0.47)($0.47)
Q3 20171($0.56)($0.56)($0.56)
Q4 20171($0.67)($0.67)($0.67)
Q1 20181($0.60)($0.60)($0.60)
Q2 20181($0.72)($0.72)($0.72)
Q3 20181($0.83)($0.83)($0.83)
Q4 20181($0.80)($0.80)($0.80)
(Data provided by Zacks Investment Research)


Dividend History for AnaptysBio (NASDAQ:ANAB)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for AnaptysBio (NASDAQ:ANAB)
Institutional Ownership Percentage: 72.59%
Insider Trades by Quarter for AnaptysBio (NASDAQ:ANAB)
Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)
Insider Trades by Quarter for AnaptysBio (NASDAQ:ANAB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/31/2017Healthcare Vii L.P. FrazierMajor ShareholderBuy400,000$15.00$6,000,000.00View SEC Filing  
1/31/2017Nicholas LydonDirectorBuy16,666$15.00$249,990.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for AnaptysBio (NASDAQ:ANAB)
Latest Headlines for AnaptysBio (NASDAQ:ANAB)
DateHeadline logoETFs with exposure to AnaptysBio, Inc. : July 24, 2017 - July 24 at 6:19 PM logoAnaptysBio, Inc.'s (NASDAQ:ANAB) Lock-Up Period Set To End on July 25th - July 18 at 10:49 AM logoAnaptysBio, Inc. (NASDAQ:ANAB) Upgraded to Hold by Zacks Investment Research - July 17 at 4:04 PM logoETFs with exposure to AnaptysBio, Inc. : July 14, 2017 - July 14 at 5:42 PM logoAnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : July 13, 2017 - July 13 at 4:37 PM logoRobert W. Baird Initiates Coverage on AnaptysBio, Inc. (NASDAQ:ANAB) - July 10 at 7:14 PM logoAnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of "Buy" from Brokerages - July 10 at 7:06 PM logo$3.13 Million in Sales Expected for AnaptysBio, Inc. (ANAB) This Quarter - July 9 at 8:13 AM logoZacks: Analysts Anticipate AnaptysBio, Inc. (ANAB) Will Post Earnings of -$0.47 Per Share - July 7 at 10:20 PM logoZacks: AnaptysBio, Inc. (ANAB) Receives Average Recommendation of "Strong Buy" from Analysts - July 5 at 9:39 AM logoAnaptysBio, Inc. – Value Analysis (NASDAQ:ANAB) : June 28, 2017 - June 28 at 4:06 PM logoAnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : June 27, 2017 - June 27 at 3:37 PM logoBrokerages Expect AnaptysBio, Inc. (ANAB) to Post ($0.47) EPS - June 14 at 6:38 PM logo Brokerages Expect AnaptysBio, Inc. (ANAB) Will Announce Earnings of -$0.47 Per Share - June 13 at 8:10 PM logoWhy AnaptysBio (ANAB) Could Be Positioned for a Slump - June 9 at 3:51 PM logoAnaptysBio to Participate in Upcoming Investor Conferences - June 1 at 3:47 PM logoAnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : May 29, 2017 - May 29 at 3:54 PM logoZacks: AnaptysBio Inc (ANAB) Receives Consensus Recommendation of "Strong Buy" from Brokerages - May 29 at 9:06 AM logo Analysts Expect AnaptysBio Inc (ANAB) Will Post Earnings of -$0.47 Per Share - May 17 at 8:28 AM logoEquities Analysts Offer Predictions for AnaptysBio Inc's Q2 2017 Earnings (ANAB) - May 17 at 8:08 AM logoAnaptysBio Inc (ANAB) Releases Earnings Results - May 12 at 11:26 AM logoAnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update - May 11 at 8:49 PM logoAnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : May 11, 2017 - May 11 at 3:47 PM logoZacks: Brokerages Set $37.67 Target Price for AnaptysBio Inc (ANAB) - May 4 at 11:02 PM logoStifel Nicolaus Reaffirms "Buy" Rating for AnaptysBio Inc (ANAB) - May 2 at 1:28 PM logo$1.63 Million in Sales Expected for AnaptysBio Inc (ANAB) This Quarter - April 28 at 5:33 PM logo-$0.25 Earnings Per Share Expected for AnaptysBio Inc (ANAB) This Quarter - April 26 at 11:44 AM logoZacks Investment Research Downgrades AnaptysBio Inc (ANAB) to Sell - April 25 at 6:16 PM logoAnaptysBio, Inc. – Value Analysis (NASDAQ:ANAB) : April 20, 2017 - April 20 at 3:36 PM logoAnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : April 19, 2017 - April 19 at 3:31 PM logoAnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : April 19, 2017 - April 19 at 3:31 PM logoAnaptysBio's (ANAB) "Outperform" Rating Reaffirmed at Credit Suisse Group AG - April 18 at 4:52 PM logoZacks: AnaptysBio Inc (ANAB) Given Consensus Rating of "Strong Buy" by Brokerages - April 18 at 10:34 AM logoETFs with exposure to AnaptysBio, Inc. : April 5, 2017 - April 7 at 5:50 AM logoAnaptysBio Announces First-In-Human Dosing of ANB019 - April 7 at 5:50 AM logo AnaptysBio Inc (ANAB) Given Consensus Recommendation of "Strong Buy" by Analysts - April 6 at 9:34 AM logoJMP Securities Reaffirms "Outperform" Rating for AnaptysBio Inc (ANAB) - April 6 at 9:31 AM logoAnaptysBio Inc (ANAB) Given New $28.00 Price Target at Wedbush - April 4 at 8:11 AM logoAnaptysBio Inc (ANAB) to Post Q1 2018 Earnings of ($0.60) Per Share, Wedbush Forecasts - March 31 at 1:05 PM logoAnaptysBio Inc (ANAB) Earns Outperform Rating from JMP Securities - March 31 at 12:02 PM logoAnaptysBio Inc (ANAB) Stock Rating Reaffirmed by Wedbush - March 29 at 4:37 PM logoAnaptysBio Inc (ANAB) Coverage Initiated at JMP Securities - March 26 at 2:25 PM logoCoverage initiated on AnaptysBio by Credit Suisse, Wedbush, Stifel and JMP Securities - February 22 at 8:35 PM logoCoverage initiated on AnaptysBio by Wedbush and Stifel - February 21 at 3:48 PM logoAnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings - February 21 at 7:54 AM logoRobust Start for Pharmaceutical IPOs In 2017 - February 6 at 3:17 PM logo[$$] Braeburn Pharmaceuticals Puts IPO Plans On Hold - February 2 at 8:34 PM logo[$$] Shares in Two Biotechs Rise Post-IPO - January 31 at 8:45 PM logoAnaptysBio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - January 31 at 8:45 PM



AnaptysBio (ANAB) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff